These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 7706807)

  • 1. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels.
    Hogervorst E; Jurriaans S; de Wolf F; van Wijk A; Wiersma A; Valk M; Roos M; van Gemen B; Coutinho R; Miedema F
    J Infect Dis; 1995 Apr; 171(4):811-21. PubMed ID: 7706807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
    Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
    Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.
    Binley JM; Klasse PJ; Cao Y; Jones I; Markowitz M; Ho DD; Moore JP
    J Virol; 1997 Apr; 71(4):2799-809. PubMed ID: 9060635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?
    Jurriaans S; Van Gemen B; Weverling GJ; Van Strijp D; Nara P; Coutinho R; Koot M; Schuitemaker H; Goudsmit J
    Virology; 1994 Oct; 204(1):223-33. PubMed ID: 7916514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome.
    Katzenstein TL; Pedersen C; Nielsen C; Lundgren JD; Jakobsen PH; Gerstoft J
    AIDS; 1996 Feb; 10(2):167-73. PubMed ID: 8838704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion.
    Farzadegan H; Henrard DR; Kleeberger CA; Schrager L; Kirby AJ; Saah AJ; Rinaldo CR; O'Gorman M; Detels R; Taylor E; Phair JP; Margolick JB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(5):448-55. PubMed ID: 8970472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1.
    Geffin RB; Scott GB; Melenwick M; Hutto C; Lai S; Boots LJ; McKenna PM; Kessler JA; Conley AJ
    AIDS Res Hum Retroviruses; 1998 May; 14(7):579-90. PubMed ID: 9591712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection.
    Janvier B; Mallet F; Cheynet V; Dalbon P; Vernet G; Besnier JM; Choutet P; Goudeau A; Mandrand B; Barin F
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):898-903. PubMed ID: 8315575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.
    Kahn JO; Steimer KS; Baenziger J; Duliege AM; Feinberg M; Elbeik T; Chesney M; Murcar N; Chernoff D; Sinangil F
    J Infect Dis; 1995 May; 171(5):1343-7. PubMed ID: 7751714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection].
    Sorice F; Vullo V; Cirelli A; Catania S; Mastroianni CM; Contini C; Delia S
    Boll Ist Sieroter Milan; 1989; 68(2):115-21. PubMed ID: 2562362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.
    Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
    Clin Exp Immunol; 1995 Feb; 99(2):175-81. PubMed ID: 7851008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value.
    Robert-Guroff M; Roilides E; Muldoon R; Venzon D; Husson R; Marshall D; Gallo RC; Pizzo PA
    J Infect Dis; 1993 Mar; 167(3):538-46. PubMed ID: 7680059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and late HIV-1 RNA level and its association with other markers and disease progression in long-term AIDS-free homosexual men.
    Spijkerman IJ; Prins M; Goudsmit J; Veugelers PJ; Coutinho RA; Miedema F; de Wolf F
    AIDS; 1997 Sep; 11(11):1383-8. PubMed ID: 9302449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection.
    Dyer WB; Zaunders JJ; Yuan FF; Wang B; Learmont JC; Geczy AF; Saksena NK; McPhee DA; Gorry PR; Sullivan JS
    Retrovirology; 2008 Dec; 5():112. PubMed ID: 19077215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1.
    Thomas HI; Wilson S; O'Toole CM; Lister CM; Saeed AM; Watkins RP; Morgan-Capner P
    Clin Exp Immunol; 1996 Feb; 103(2):185-91. PubMed ID: 8565298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity and specificity of anti-HIV ELISA employing recombinant (p24, p66, gp120) and synthetic (gp41) viral antigenic peptides.
    Filice G; Soldini L; Orsolini P; Razzini E; Gulminetti R; Campisi D; Chiapparoli L; Cattaneo E; Achilli G
    Microbiologica; 1991 Jul; 14(3):185-94. PubMed ID: 1717811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus type 1 disease progression, CCR5 genotype, and specific immune responses.
    Visco-Comandini U; Hultgren C; Broström C; Birk M; Kim S; Sällberg M
    Clin Diagn Lab Immunol; 1998 Jul; 5(4):463-6. PubMed ID: 9665949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS.
    Strathdee SA; Frank JW; McLaughlin J; Leblanc M; Major C; O'Shaughnessy MV; Read SE
    J Infect Dis; 1995 Nov; 172(5):1375-9. PubMed ID: 7594682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.